2155-18

2155-18 is a preclinical small molecule inhibitor that targets the spliceosomal proteins hnRNPH1 and hnRNPH2. Developed by researchers at Nova Southeastern University, Queens College, and Moffitt Cancer Center, it is being investigated for the treatment of advanced melanoma, including cases resistant to BRAF and NRAS inhibitors. The compound works by downregulating these spliceosomal proteins, which leads to tumor growth inhibition and enhanced immune cell infiltration into the tumor microenvironment. In preclinical mouse models, 2155-18 demonstrated significant anti-tumor efficacy and a favorable safety profile, supporting its potential development as a monotherapy or in combination with immunotherapies.